41808-35-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-3-methyl-isothiazole-4-carbonitrile is used as a building block for the synthesis of various drugs and agrochemicals, contributing to the development of new therapeutic agents and crop protection products.
Used in Organic Synthesis:
5-Amino-3-methyl-isothiazole-4-carbonitrile is used as a versatile chemical intermediate for the preparation of diverse heterocyclic compounds, which are important in the synthesis of complex organic molecules and pharmaceuticals.
Used in Antimicrobial and Antifungal Applications:
5-Amino-3-methyl-isothiazole-4-carbonitrile has been studied for its potential biological activities, including antimicrobial and antifungal properties, making it a candidate for use in the development of new antimicrobial and antifungal agents to combat resistant strains and infections.

InChI:InChI=1/C5H5N3S/c1-3-4(2-6)5(7)9-8-3/h7H2,1H3

Upstream product

• 89943-20-4 2-cyano-3-ethoxythiocrotonamide 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 116595-42-7 (2E)-2-cyano-3-ethoxybut-2-enethioamide 
• 758721-53-8 (2E)-3-amino-2-cyanobut-2-enethioamide 
• 41808-30-4 3-amino-2-cyano-but-2-enethioic acid amide 
• 49779-27-3 (4-cyano-3-methyl-isothiazol-5-yl)-carbamic acid phenyl ester 

Downstream Products

• 41808-40-6 5-Amino-3-methylisothiazol-4-carboxamid 
• 758721-55-0 5-benzyl-3-methyl-6-propyl-[1,2]thiazolo[4,5-e]pyrimidin-4-one 
• 876191-26-3 5-[(3-fluorophenyl)methyl]-3-methyl-6-propyl-[1,2]thiazolo[4,5-e]pyrimidin-4-one 
• 758721-57-2 5-benzyl-6-(1-bromopropyl)-3-methyl-[1,2]thiazolo[4,5-e]pyrimidin-4-one 
• 876191-27-4 6-(1-bromopropyl)-5-[(3-fluorophenyl)methyl]-3-methyl-[1,2]thiazolo[4,5-e]pyrimidin-4-one 
• 758721-59-4 tert-butyl N-[3-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)propylamino]propyl]carbamate 
• 876191-28-5 tert-butyl N-[3-[1-[5-[(3-fluorophenyl)methyl]-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl]propylamino]propyl]carbamate 
• 876306-71-7 tert-butyl N-[3-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)propyl-(4-methylbenzoyl)amino]propyl]carbamate 
• 758721-69-6 tert-butyl N-[3-[1-[5-[(4-fluorophenyl)methyl]-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl]propyl-(4-methylbenzoyl)amino]propyl]carbamate 
• 876191-29-6 tert-butyl N-[3-[1-[5-[(3-fluorophenyl)methyl]-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl]propyl-(4-methylbenzoyl)amino]propyl]carbamate 
• 876306-81-9 tert-butyl N-[3-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)propyl-(3-fluoro-4-methylbenzoyl)amino]propyl]carbamate 
• 758721-70-9 tert-butyl N-[3-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)propyl-(4-bromobenzoyl)amino]propyl]carbamate 

Relevant academic research and scientific papers

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4- d ]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent

Structure-activity relationship analysis identified (+)-N-(3-aminopropyl)- N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl) -2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

Selected fused heterocyclics and uses thereof

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

NOVEL FUSED HETEROCYCLES AND USES THEREOF

This invention relates to novel compounds having the formula (I) (a chemical formula should be inserted here - please see paper copy enclosed herewith) m = 0, 1, 2 n = 0, 1 (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

Ink compositions

An ink comprising water, a water-dissipatable polymer and one or more dyes of Formula (1): wherein:R1 is H or a substituent;R2 and R3 are each independently optionally substituted alkyl, aryl or aralkyl, or R2 andR3 together with the carbon atom to which they are attached form an optionally substituted ring;R4 is H or optionally substituted alkyl, aryl or aralkyl; andD is an optionally substituted arylene group. Also claimed are the dyes of Formula (1), ink jet printing processes and cartridges containing the inks.